United States Patent 12,220,401: What the Claims Cover and How the BTK Patent Landscape Likely Maps
US Patent 12,220,401 is a composition-and-method patent anchored on a specific chiral BTK-modulating compound (and pharmaceutically acceptable salts), plus downstream coverage of a formulation and BTK-related therapeutic methods across oncology and immune-mediated indications.
Because the claim set you provided is definitionally broad at the platform level (compound class structure + “pharmaceutically acceptable salt” + administering for BTK-modulated conditions), the practical claim scope hinges on (1) the exact chemical structure embedded in the “formula” clause for claim 1 and (2) whether the application defines absolute stereochemistry at the “* indicates a chiral center” positions. Those two elements control both infringement risk and landscape carve-outs by competing BTK chemotypes.
What is actually claimed in US 12,220,401?
The independent claim appears to be claim 1, with claim 2 directed to a pharmaceutical composition and claims 3-6 directed to therapeutic methods.
Claim 1 (compound scope)
- Scope: A single chemical invention defined by a structure formula.
- Variants expressly covered:
- Enantiomer(s) and/or stereoisomer(s are implicated by “* indicates a chiral center” language.
- “Or a pharmaceutically acceptable salt thereof” extends coverage to salts of the defined compound(s).
Practical implication: Claim 1 is the “gate” for infringement. If a competitor makes a compound that is outside the structural formula (even slightly) or uses a stereochemistry not encompassed by the claim’s stereochemical language, claim 1 may not be met.
Claim 2 (composition scope)
- Scope: A pharmaceutical composition comprising:
- the claimed compound (or a pharmaceutically acceptable salt), and
- pharmaceutically acceptable excipients.
- No dosage regimen is specified in the excerpt, so the claim typically covers standard formulation forms (tablets, capsules, oral solutions, etc.) as long as they include the claimed active.
Practical implication: Composition claims are often easy to satisfy for any approved or developed formulation of the same active ingredient, but hard to design around when the active is off-limits.
Claim 3 (method of treating by administering the compound)
- Scope: A method of treating a condition “modulated by BTK” by administering:
- the claimed compound (or salt).
Practical implication: “BTK” modality is a powerful functional anchor. Competitors can try to avoid literal claim coverage only by:
- not using the compound/salt of claim 1, or
- targeting a different molecular mechanism and arguing non-BTK modulation, which may not work if their compound inherently modulates BTK signaling in the claimed patient population.
Claims 4-6 (indication narrowing and lists)
- Claim 4 narrows “BTK-modulated conditions” to a group including:
- cancer, lymphoma, leukemia
- autoimmune diseases, inflammatory disorders
- heteroimmune conditions
- fibrosis
- Claim 5 provides a long selected list including:
- B-cell malignancy, B-cell lymphoma, DLBCL (ABC-DLBCL), mantle cell lymphoma, follicular lymphoma
- chronic lymphocytic leukemia
- non-Hodgkin lymphoma, hairy cell leukemia
- Waldenstrom’s macroglobulinemia
- multiple myeloma
- bone cancer, bone metastasis
- arthritis, multiple sclerosis, osteoporosis
- IBS, IBD, Crohn’s disease
- Sjögren’s syndrome, lupus
- Claim 6 narrows further to:
- arthritis, multiple sclerosis, osteoporosis, IBS, IBD, Crohn’s disease, lupus
Practical implication: Claims 4-6 increase leverage for enforcement across both oncology and immune/inflammation. The nested list structure also reduces the design-around value of choosing a different indication: the claim lists are broad and overlap major BTK-driven areas (e.g., CLL, NHL, autoimmune disease).
What is the likely “scope boundary” of claim 1 (and why it matters)?
Even without the chemical structure text in your prompt, claim 1’s boundary is set by:
- The exact formula (ring system, substituents, heteroatoms, linkers, and attachment points)
- Chiral center definition
- “* indicates a chiral center” can mean:
- a specific stereoisomer, or
- a broader stereochemical set (depending on whether the formula text includes absolute configuration descriptors like R/S, wedge/dash depiction, or stereochemical claim language).
- Salt coverage
- “pharmaceutically acceptable salt” typically captures hydrochlorides, sulfates, fumarates, citrates, etc., unless the specification restricts salts to a defined list (not provided here).
Landscape consequence: Most BTK competitors fall into known chemotype families (covalent vs non-covalent; reversible vs irreversible; distinct scaffold classes). If US 12,220,401 is scaffold-specific, infringement risk is highly sensitive to whether competitors use the same scaffold and stereochemistry.
How broad is the functional “BTK-modulated condition” language?
Claim 3 is anchored to “a condition which is modulated by BTK in a patient in need thereof.” This does two things in practice:
- It does not require the claim to name a mechanism beyond BTK modulation.
- It creates a plausible nexus for many downstream therapeutic areas where BTK signaling is implicated.
Claims 4-6 then enumerate specific categories and diseases. That enumeration typically reduces arguments that the method is too indefinite or too far afield, because many named indications are standard BTK therapy targets.
Landscape consequence: A competitor trying to argue their indication is not covered must overcome both:
- the functional BTK modulation language in claim 3, and
- the disease lists in claims 4-6.
What does this likely mean for design-around strategy?
Given the claim set you provided, a design-around has three main levers:
- Avoid the claim-1 compound entirely
- Change the chemical formula (scaffold/substituent pattern) so it no longer matches the defined formula.
- Avoid encompassed stereochemistry/salt form (if stereochemistry is limited)
- If claim 1 is limited to a particular stereoisomer, using the opposite stereoisomer (or non-covered stereochemical ensemble) can avoid literal infringement.
- If claim language is broad and covers all stereoisomers permitted by the formula, this lever is weak.
- Avoid the method claim by mechanism-of-action arguments
- If a compound does not modulate BTK in the claimed patient population, a method claim may be avoidable.
- If the compound is a true BTK inhibitor (covalent or reversible) and shows BTK pathway modulation, mechanism arguments face higher resistance.
In practice, the first lever (chemical non-equivalence) is the strongest.
BTK Patent Landscape Positioning for US 12,220,401
How does US 12,220,401 stack against the typical BTK IP pattern?
US BTK portfolios in the market often split across four IP lanes:
- Core compound claims (structure + salts)
- Stereochemistry or polymorph claims
- Formulation claims (excipients, dosage forms)
- Use claims (method of treating BTK-modulated diseases, patient populations, and combinations)
Your provided claim set fits lanes 1-4 in a single family:
- claim 1: core compound
- claim 2: composition with excipients
- claim 3: administering to treat BTK-modulated conditions
- claims 4-6: explicit disease list narrowing
Business implication: If US 12,220,401 is tied to a commercially relevant BTK compound, it likely blocks both generic entry at the active level and “workalike” entry via common formulation approaches.
Which competing BTK classes are most likely to collide (high level)?
Without the chemical formula content, the safest landscape inference is structural: BTK competitive space has both covalent and reversible inhibitors and multiple scaffold families. Claim 1 collisions typically occur when competitors share:
- the same or closely related scaffold pattern required by the formula, and
- overlapping stereochemistry definitions.
If US 12,220,401 is a close analog to established BTK inhibitors, it still may be protected even if competitors choose different modality (because method claims remain active as long as the patented compound is administered).
Claim Construction: What courts will likely focus on
*How are the “ indicates a chiral center” features interpreted?**
Courts usually look at:
- how the patent drawings/description specify stereochemistry, and
- whether the claim language intends to cover one stereoisomer or multiple.
Because you provided only the “* indicates a chiral center” placeholder, the litigation-critical question is whether the patent defines absolute configuration for each chiral center within the formula.
Practical litigation impact:
- If the claim covers multiple stereoisomers, competitors lose the stereochemical carve-out.
- If the claim is limited to a particular stereochemical set, competitors can design around using non-covered stereoisomers.
How do “pharmaceutically acceptable excipients” and “salt” affect enforceability?
These are typically broad categories. “Pharmaceutically acceptable” is usually not a meaningful restriction unless the spec defines a narrow list of excipients/salts.
Practical impact:
- claim 2 likely has low design-around value unless competitors can avoid using the exact compound/salt.
Infringement Map: where the claims likely hit
Direct infringement pathways
A party can meet claim 1/2 if they:
- manufacture, import, sell, or use the claimed compound/salt, or
- sell a formulation that includes it.
A party can meet claim 3/4/5/6 if they:
- administer the claimed compound to a patient with a BTK-modulated condition named or included by the claims.
Indirect infringement exposure
If enforcement is pursued, upstream suppliers (API manufacturers) typically face:
- contributory infringement exposure if they supply a compound that is used in covered methods,
- and inducement exposure if they market for BTK indications covered by claims 4-6.
Key Takeaways
- US 12,220,401’s core claim is compound-defined (claim 1), with salt coverage and stereochemistry keyed to chiral centers referenced in the formula.
- The IP extends beyond the API into formulations (claim 2) and BTK-treatment methods (claim 3), then broadens enforcement coverage through nested disease lists covering major B-cell malignancies and immune/inflammatory diseases (claims 4-6).
- Design-around is primarily chemical: avoiding the claim-defined structure (and potentially stereochemistry/salt) is the most durable path. Indication changes alone likely do not avoid method claim scope because the claims enumerate and overlap standard BTK areas.
- Landscape collision risk is highest for any developer whose candidate is the same (or stereochemically encompassed) BTK compound or a true equivalent that falls within the same structural formula.
FAQs
1) Does US 12,220,401 cover both the compound and its use?
Yes. Claim 1 covers the compound (and salts), claim 2 covers a pharmaceutical composition including it, and claims 3-6 cover treating BTK-modulated conditions by administering the compound.
2) How do the disease lists in claims 4-6 change the scope?
They narrow the method claim’s covered indications while still covering major BTK-linked oncology and immune/inflammatory conditions. The lists reduce arguments that the method is too broad relative to BTK biology.
3) Is avoiding a BTK indication enough to escape claims 3-6?
Not reliably. Claim 3 ties coverage to “BTK-modulated” conditions, and claims 4-6 enumerate multiple overlapping diseases. A different label may not avoid coverage if the patient is treated for a covered BTK-modulated condition.
4) What is the main design-around lever?
Avoiding the claim-1 compound structure (and, depending on claim stereochemical interpretation, avoiding encompassed stereoisomers and salts).
5) Does claim 2 provide meaningful additional protection?
Yes. It covers formulations that contain the patented compound with pharmaceutically acceptable excipients, which can block common generics or formulation-only workarounds if the active is the same.
References
[1] US Patent 12,220,401 (claims provided in prompt).
